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OBJECTIVE The aim of this study was to determine the effect of prophylactic immune suppression on the
incidence and severity of postpericardiotomy syndrome (PPS) in children after cardiac surgery
with cardiopulmonary bypass (CPB).
BACKGROUND Prophylactic suppression of the inflammatory response has an unknown effect on the
incidence and severity of PPS in children undergoing surgery with CPB.
METHODS This randomized double-blind placebo controlled trial included two study groups. Group A
received pre-CPB intravenous methylprednisolone (1 mg/kg) plus four additional intravenous
doses over 24 h, and Group B received intravenous saline placebo at identical intervals. Data
included patient demographics, cardiac diagnosis/operation, CPB time, incidence and
severity of PPS. Noncomplicated PPS—temperature .100.5°F, pericardial friction rub,
patient irritability, small pericardial 6 pleural effusion. Complicated PPS—noncomplicated
PPS plus hospital readmission 6 pericardiocentesis or thoracentesis.
RESULTS We randomized 266 children: 20 exclusions (6 perioperative deaths, 14 reasons unrelated to
treatment) leaving Group A (n 5 126) and Group B (n 5 120). There were no significant
group differences in gender, cardiac diagnosis or CPB time. Group mean age differed (p 5
0.05) and was treated as a covariate with no substantive outcome effect. In total, 39/246
children (16%) developed PPS (noncomplicated: n 5 30, complicated: n 5 9). There was no
inter-group difference in overall PPS incidence (p 5 0.73). However, Group A had a
marginally significant increase in complicated PPS (p 5 0.05).
CONCLUSIONS Intravenous methylprednisolone at a standard anti-inflammatory dose administered pre-CPB
and early post-CPB neither prevents nor attenuates PPS in children. Short-term pre-CPB
and post-CPB methylprednisolone treatment may complicate PPS. (J Am Coll Cardiol
2001;37:1700–6) © 2001 by the American College of Cardiology
Postpericardiotomy syndrome (PPS) resulting from an in-
flammatory response occurs in as many as 30% of children
undergoing cardiac surgery (1–4). Clinical features of PPS
include fever, irritability and malaise. These clinical features
are commonly accompanied by the development of peri-
cardial or pleural effusions. The diagnosis of PPS adds
significant perioperative morbidity and cost to the manage-
ment of these patients which is due, in part, to additional
noninvasive testing (e.g., echocardiography and chest radio-
graphs), medical therapy and the not uncommon need for
hospital readmission and invasive therapy (pericardiocente-
sis or thoracentesis).
Previous studies suggest that the inflammatory process
responsible for PPS is a humoral immune response triggered
by cardiac antigen exposure (5–7). These data would suggest
that prophylactic pharmacologic immune suppression would
attenuate the course of PPS. Indeed, postdiagnostic treat-
ment of PPS with nonsteroidal anti-inflammatory agents
(e.g., aspirin and ibuprofen) and glucocorticosteroids (e.g.,
methylprednisolone) is usually very effective (8–11). How-
ever, to date, no prophylactic immunosuppressive clinical
trial has been performed.
The objective of this randomized double-blind placebo-
controlled clinical trial was to determine the effect of
short-term prophylactic immune suppression on the inci-
dence and severity of PPS in a cohort of pediatric patients
who had undergone cardiac surgery using cardiopulmonary
bypass (CPB).
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METHODS
Our research protocol was approved by the Baylor College
of Medicine Affiliates and Texas Children’s Hospital Re-
view Boards for human subject research. The study design
was a randomized double-blind placebo-controlled trial that
included two study groups. The treatment group received
prophylactic immunosuppression in the form of intravenous
methylprednisolone preoperatively and for the first 24 h
after surgery. The control group received an intravenous
placebo (normal saline) preoperatively and at identical
intervals as the treatment group.
Patient enrollment. Patients were enrolled between
March 1996 and June 1998. Inclusion criteria included
patients between 1 day and 18 years of age with congenital
heart disease who were undergoing cardiac surgery with
CPB. Exclusion criteria included patients with a known
allergy to methylprednisolone, patients being treated with a
steroid for chronic immune suppression, and patients with
previously documented hematologic, hepatic or renal dys-
function.
Before patient enrollment, a study investigator obtained
informed consent from the patient’s parents (or legal guard-
ians). A study-coordinating nurse (not involved in direct
patient care or treatment effectiveness evaluation) assigned
each patient a study number from the randomization table
that was created by the study statistician.
Treatment course. PREOPERATIVE ADMINISTRATION. On
the day of surgery, the hospital pharmacy personnel pro-
vided the attending anesthesiologist a patient-labeled sy-
ringe containing either methylprednisolone (1 mg/kg/dose)
for the treatment group patient or a syringe of weight-
equivalent volume of placebo (normal saline) for the control
group patient. The drug or placebo was administered to the
patient in the operative suite at the same time the prophy-
lactic intravenous antibiotic was given, which was before the
initial skin incision.
POSTOPERATIVE ADMINISTRATION. For the first 24 h after
cardiac surgery, the treatment group patients received intra-
venous methylprednisolone (1 mg/kg/dose) every 6 h for a
total of four doses. Control group patients received a
weight-equivalent intravenous volume of placebo every 6 h
for a total of four doses. In order to maintain provider
blinding, both methylprednisolone and placebo dosages
were prepared and dispensed by the hospital pharmacy.
Intravenous cimetidine was administered for gastric mucosal
protection to all patients.
Test parameters. Data extraction included age, gender,
cardiac diagnosis, cardiac surgery, CPB time and diagnosis
and severity of PPS. A complete postoperative echocardio-
gram was routinely performed on each patient between 7
and 10 days after cardiac surgery or earlier, if indicated. The
severity of PPS was defined as either noncomplicated or
complicated. Noncomplicated PPS was defined as the
presence of temperature .100.5°F, patient irritability, peri-
cardial friction rub, small pericardial effusion 6 pleural
effusion. Complicated PPS was defined as having clinical
features of noncomplicated PPS with an additional need for
hospital readmission 6 the need for pericardiocentesis 6
thoracentesis. Patients with incidentally observed small
pericardia or pleural effusions in the absence of other
symptoms or signs of PPS were not included in the PPS
cohort.
Criteria for early termination from study. Patients were
terminated from the study, and blinding for treatment was
broken if the patient developed an allergic reaction to the
treatment drug/placebo or if he or she was diagnosed with
PPS as described above. Each patient was followed in order
to assess the severity of the allergic reaction or to assess the
occurrence of PPS.
Data analysis. The necessary sample size was determined
to be 266 patients. This calculation was based on the
hypothesis of a reduction in the incidence of PPS from 15%
to 5% with a power of at least 80% and an alpha level of
0.05. Treatment groups were compared with respect to
baseline characteristics using chi-square analysis for propor-
tions and Student t test for means. Baseline variables that
differed between treatment groups were treated as covariates
in a binary logistic regression analysis that simultaneously
included group and covariates in the model. This model was
also used to test for interaction between treatment group
and covariates.
RESULTS
Study cohort. A total of 266 patients were randomized to
one of two groups: treatment or control group. Twenty
patients were excluded from analysis before unblinding of
the data due either to perioperative death (n 5 6) or
deviations from the treatment protocol (n 5 14), which
included preoperative steroid use, error in dosage of the
treatment drug or placebo and the need for additional
administration of steroids in the perioperative period. The
remaining 246 patients comprised the total study popula-
tion: treatment group (n 5 126) and control group (n 5
120). The overall 30-day surgical mortality for the 266
patients was 2.2%. No patient deaths were attributed to the
presence of pericardial effusions or pleural effusions in
association with a diagnosis of PPS.
The demographic data of the total study cohort were
compared for group differences. Variables included patient
age, gender, mean cardiopulmonary bypass time, cardiac
diagnosis and cardiac surgery. Table 1 addresses the vari-
ables of cardiac diagnosis and cardiac surgery. The mean age
for the treatment group patients was 36.6 months versus
44.0 months for the control group patients (p 5 0.05).
Abbreviations and Acronyms
CPB 5 cardiopulmonary bypass
PPS 5 postpericardiotomy syndrome
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Using logistic regression, age was treated as a covariate and
determined not to have a substantive effect on outcome.
There were 70 male/56 female patients in the treatment
group and 67 male/53 female patients in the control group
(p 5 0.79). The mean CPB time for the treatment group
was 136 6 63 min compared with 140 6 78 min for the
control group patients (p 5 0.71).
PPS cohort. NONCOMPLICATED AND COMPLICATED PPS
SUBGROUPS. The demographic data of patients diagnosed
with PPS (noncomplicated and complicated) were com-
pared for group differences. Variables included patient age,
gender, CPB time, cardiac diagnosis and cardiac surgery.
There were 39/246 (16%) patients who met criteria for the
diagnosis of PPS (noncomplicated and complicated). Nine-
teen of the 39 (49%) had either ventricular septal defect
Table 1. Total Study Cohort (n 5 246)
Cardiac Diagnosis and Cardiac Surgery
Control
Group
(n 5 120)
(%)
Treatment
Group
(n 5 126)
(%)
Isolated Semilunar Valve Stenosis
or Regurgitation
(6%) (4%)
c Aortic valvuloplasty/replacement 3 4
c Ross operation 3 0
c Pulmonary valvotomy/homograft
placement
1 1
Septal Defects (34%) (36%)
c ASD closure 21 16
c VSD closure 17 26
c ASD/VSD closure 3 3
Isolated Atrioventricular Valve Stenosis/
Regurgitation
(9%) (2%)
c Tricuspid valvuloplasty/replacement 2 0
c Mitral valvuloplasty/replacement 9 2
Complete Atrioventricular Canal Defect (3%) (6%)
c Definitive repair 4 7
Coarctation of the Aorta 6 VSD
and IAA
(4%) (5%)
c Aortic arch advancement 6 VSD closure 4 5
c IAA/VSD—Aortic arch repair with
VSD closure
1 1
Functional Single Ventricle (13%) (9%)
c Bidirectional Glenn shunt 12 8
c Fontan operation 3 4
Right Ventricular Outflow Tract Defects (12%) (11%)
c Tetralogy of Fallot
Definitive repair 11 11
c Pulmonary valve atresia/intact ventricular
septum
Pulmonary arterioplasty 2 1
Right ventricle muscle resection 6
ASD closure
1 2
Truncus Arteriosus/Hemitruncus (1%) (1%)
c Pulmonary artery unifocalization/VSD
closure
1 0
c Pulmonary or aortic homograft
placement
0 1
Left Ventricular Outflow Tract Defects (6%) (6%)
c Subaortic stenosis 6 VSD
Subaortic stenosis resection 6 VSD
closure
3 5
c Hypoplastic left heart syndrome
Stage 1 neonatal reconstruction 5 3
Transposition of the Great Artery
Sequences
(8%) (10%)
c D-TGA 6 VSD
Arterial switch operation 6 VSD
closure
6 10
c D-TGA/VSD/PS
Rastelli procedure 2 3
c L-TGA/VSD/PS
Senning operation/arterial switch
operation
1 0
Total Anomalous Pulmonary Venous
Connection
(3%) (6%)
c Total correction 4 8
Other (1%) (4%)
1 5
ASD 5 atrial septal defect; IAA 5 interrupted aortic arch; PS 5 pulmonary valve
stenosis; TGA 5 transposition of the great artery; VSD 5 ventricular septal defect.
Table 2. Comparison of Patients With PPS (Noncomplicated
and Complicated)
Control
Group
18/120
Treatment
Group
21/126
Demographic Data
Age (months) 38 (638) 42 (630)
Gender (male/female) 9/9 9/12
Mean CPB time (min) 136 (654.3) 117 (653.4)
Cardiac Diagnosis and Repair
Isolated Semilunar Valve Stenosis
or Regurgitation
c Aortic valvuloplasty/replacement 1 0
Septal Defects
c ASD closure 3 6
c VSD closure 4 3
c ASD/VSD closure 1 0
Isolated Atrioventricular Valve
Stenosis/Regurgitation
c Tricuspid valvuloplasty/replacement 2 0
Complete Atrioventricular Canal
Defect
c Definitive repair 1 3
Functional Single Ventricle
c Fontan operation 0 1
Left Ventricular Outflow Tract Defects
c Subaortic stenosis 6 VSD
Subaortic ridge resection 6 VSD
closure
0 1
Coarctation of the Aorta 6 VSD
c Coarctectomy and aortic arch
advancement
1 0
Right Ventricular Outflow Tract
Defects
c Tetralogy of Fallot 2 4
Definitive repair
c Pulmonary atresia/intact ventricular
septum
Pulmonary arterioplasty 0 1
Right ventricle muscle resection 6
ASD closure
1 0
Transposition of the Great Artery
c Transposition of the great artery 6 VSD 2 1
Arterial switch operation
Other 0 1
ASD 5 atrial septal defect; CPB 5 cardiopulmonary bypass; PPS 5 postpericar-
diotomy syndrome; VSD 5 ventricular septal defect.
1702 Mott et al. JACC Vol. 37, No. 6, 2001
Postpericardiotomy Syndrome in Children After Cardiac Surgery May 2001:1700–6
(n 5 10), atrial septal defect (n 5 8) or ventricular septal
defect/atrial septal defect (n 5 1). Postpericardiotomy
syndrome (noncomplicated and complicated) was diagnosed
in 21/126 (17%) treatment group patients and 18/120 (15%)
control group patients (p 5 0.73) (Table 2).
A pericardial effusion was present on echocardiogram in
39/39 (100%), temperature .100.5°F in 33/39 (85%),
“patient irritability” was described in 18/39 (46%), and a
pericardial friction rub was auscultated in 18/39 (46%).
Pleural effusions were noted on chest radiographs in 13/39
(33%).
The median postoperative day of the initial diagnosis of
PPS was seven days (range 4 to 42 days). Eleven of the 39
(28%) were diagnosed after hospital discharge. The median
postoperative hospital length of stay was seven days (range 2
to 27 days). The median postoperative length of stay for
those 207 patients without PPS was seven days (range 3 to
120 days).
NONCOMPLICATED PPS SUBGROUP. Of the 39 patients with
PPS (noncomplicated and complicated), 30 met criteria for
the diagnosis of noncomplicated PPS. Thirteen of 126
(10%) were treatment group patients, and 17/120 (14%)
were control group patients. The demographic data of
patients diagnosed with noncomplicated PPS were com-
pared for group differences. Variables included patient age,
gender, CPB time, cardiac diagnosis and cardiac surgery
(Table 3).
A small to moderate sized pericardial effusion was present
on echocardiogram in 30/30 patients (100%), temperature
.100.5°F was present in 28/30 patients (93%), “patient
irritability” was described in 15/30 patients (50%), and a
pericardial friction rub was auscultated in 15/30 patients
(50%). Pleural effusions were noted on chest radiographs in
7/30 patients (23%).
The median postoperative day of the diagnosis of non-
complicated PPS was seven days (range 4 to 15 days). Six of
the 30 patients with noncomplicated PPS were diagnosed after
hospital discharge. The median postoperative hospital length
of stay for the group was eight days (range 2 to 27 days).
COMPLICATED PPS SUBGROUP. Nine of 39 patients (23%)
of the PPS cohort, and 9/246 patients (4%) of the total
study cohort met criteria for the diagnosis of complicated
PPS (noncomplicated PPS plus need for hospital readmis-
sion 6 pericardiocentesis or thoracentesis). Eight of the 126
patients (6%) were treatment group patients, and 1/120
patients (0.8%) was a control group patient (p 5 0.05).
The mean age for the eight treatment group patients was
55 (657) months. There were seven female patients and
one male patient. The mean CPB time was 124 (654.3)
min. Four patients had septal defects: atrial (n 5 3) and
ventricular (n 5 1). One patient each had complete atrio-
ventricular canal defect, tetralogy of Fallot, pulmonary valve
atresia with an intact ventricular septum and L-transposition of
the great arteries with a ventricular septal defect. The one
control group patient was a 48-month-old female patient
with an atrial septal defect. The CPB time was 49 min.
At presentation, 9/9 patients had moderate to large
circumferential clinically significant pericardial effusions.
Temperature .100.5°F was present in 5/9 (55%), “patient
irritability” was described in 3/9 (33%), and a pericardial
friction rub was auscultated in 3/9 (33%). Six of the nine
patients (67%) had an associated pleural effusion. Each
patient was symptomatic with tachypnea and labored
breathing. One patient presented with cardiac tamponade.
Intravenous methylprednisolone therapy and diuretic
therapy resolved the pericardial effusion in 4/9 patients,
while five patients required invasive therapy—pericardio-
centesis (n 5 4) and surgical creation of a pericardial
window (n 5 1). Six of the nine patients (67%) had an
Table 3. Comparison of Patients: Noncomplicated PPS
Control
Group
17/120
Treatment
Group
13/126
Demographic Data
Age (months) 38 (638) 34 (628)
Gender (male/female) 9/8 9/4
Mean CPB time (min) 141 (652.1) 113 (652.5)
Cardiac Diagnosis and Repair
Isolated Semilunar Valve Stenosis or
Regurgitation
c Aortic valvuloplasty/replacement 1 0
Septal Defects
c ASD closure 2 2
c VSD closure 4 2
c ASD/VSD closure 1 0
Isolated Atrioventricular Valve
Stenosis/Regurgitation
c Tricuspid valvuloplasty/replacement 2 0
Complete Atrioventricular Canal
Defect
c Definitive repair 1 3
Functional Single Ventricle
c Fontan operation 0 1
Left Ventricular Outflow Tract Defects
c Subaortic stenosis 6 VSD
Subaortic ridge resection 6 VSD
closure
0 1
Coarctation of the Aorta 6 VSD
c Coarctectomy and aortic arch
advancement
1 0
Right Ventricular Outflow Tract
Defects
c Tetralogy of Fallot
Definitive repair 2 3
c Pulmonary atresia/intact ventricular
septum
Right ventricle muscle resection 6
ASD closure
1 0
Transposition of the Great Artery
c Transposition of the great artery 6 VSD
Arterial switch operation 2 1
ASD 5 atrial septal defect; CPB 5 cardiopulmonary bypass; PPS 5 postpericar-
diotomy syndrome; VSD 5 ventricular septal defect.
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associated pleural effusion. In 4/6 patients, the pleural
effusion resolved with the institution of intravenous meth-
ylprednisolone and diuretic therapy, while 2/6 patients
required thoracentesis.
The median postoperative day of diagnosis of compli-
cated PPS was 10 days (range 4 to 42 days). Five of the nine
patients were diagnosed with complicated PPS as outpa-
tients after initial hospital discharge. The median initial
postoperative hospital length of stay for the group was four
days (range 2 to 26 days). The median number of total
in-hospital days (initial postoperative days plus readmission
days) was 11 days (range 7 to 30 days). One patient had two
hospital readmissions for the management of PPS with a
persistent pericardial effusion.
DISCUSSION
Postpericardiotomy syndrome: initial description and
evolving definition. In 1951, the first description of PPS
was made in a patient with rheumatic induced mitral valve
stenosis who had undergone mitral valvuloplasty (12,13).
The etiology of PPS was felt to be secondary to reactivation
of the rheumatic process. The same complex of signs and
symptoms was later described in postcardiotomy patients
who did not have rheumatic heart disease. Attention turned
to cardiopulmonary bypass as the inflammatory stimulus for
PPS (14). However, subsequent reports have described PPS
after noncardiopulmonary bypass procedures (e.g., trans-
venous pacemaker placement, radiofrequency ablation, aor-
topulmonary shunt placement and myocardial infarction)
(9,15–19).
Postpericardiotomy syndrome: proposed autoimmune
etiology theory and its challenges. In a large clinical series
of children in 1980, Engle and colleagues (3) implicated an
autoimmune process concomitant with a viral infection as a
possible etiology for PPS. Anti-heart antibody in high titer
appeared in all children diagnosed with PPS. A fourfold or
greater rise in titer to antiviral antibody was found in 70% of
those with clinical evidence of PPS, compared with only 5%
of those with negative anti-heart antibody and no clinical
evidence of PPS. A later study demonstrated an association
of PPS with circulating anti-heart antibodies and immune
complexes temporally relating immune complex formation
at the time of cardiac antigen exposure during surgery (20).
Maisch and colleagues (6) further investigated the subtypes
of specific autoantibodies and showed that 95% of their
patients with PPS had antibodies to myocardium and
skeletal muscle. These included both antisarcolemmal anti-
bodies, which were primarily IgG, and antifibrillary anti-
bodies, which were predominantly IgM. The immunoglob-
ulin type and the timing of its presence in sera suggest that
the antifibrillary IgM antibodies were related to a primary
immune response, whereas the antisarcolemmal IgG anti-
bodies were related to a secondary response. Surgery and
trauma were hypothesized etiologies for the myocardial
injury that caused the release of these myocardial antigens.
The concept that anti-heart immune complexes result in
the inflammatory response causing PPS has recently been
challenged. Webber and colleagues (14) found no evidence
that B-cell immune response to cardiac antigens leads to
PPS. Cabalka and colleagues (21) in a retrospective review
of 15 patients who had undergone orthotopic heart trans-
plantation reported 7/15 patients (47%) diagnosed with
PPS despite having been treated with immunosuppressive
therapy.
Prevention and effective treatment of postpericardiotomy
syndrome. Wilson and colleagues (9) in a double-blind
placebo-controlled trial studied the effectiveness of a 14-day
treatment course in 21 children after a diagnosis of PPS was
made. They demonstrated that prednisone hastened the
recovery of children with PPS, although some patients in
this study had larger pericardial effusions after the initiation
of therapy with prednisone. In a randomized placebo-
controlled trial in 149 adults, Horneffer and colleagues (8)
demonstrated that ibuprofen and indomethacin provided
safe and effective symptomatic treatment of PPS.
In a double-blind placebo-controlled randomized clinical
trial, we sought to assess the efficacy of short-term prophy-
lactic administration of a glucocorticosteroid (methylpred-
nisolone) in reducing the incidence and severity of PPS
in children who had undergone cardiac surgery with car-
diopulmonary bypass. We found that preoperative and
immediate postoperative administration of a parenteral
glucocorticosteroid (methylprednisolone) at a standard im-
munosuppressive dose failed to prevent or attenuate the
course of PPS in a large cohort of children undergoing
cardiac surgery with cardiopulmonary bypass.
In our study, 39/246 (16%) patients met criteria for the
diagnosis of PPS (noncomplicated and complicated), which
is a comparable incidence to other pediatric reports (4,22).
Like other investigators, we observed an overrepresentation
of some cardiac lesions. Nineteen of the 39 patients (49%)
had either ventricular septal defect (n 5 10), atrial septal
defect (n 5 8) or ventricular septal defect/atrial septal defect
(n 5 1). Patients with a primary cardiac diagnosis of atrial
septal defect or ventricular septal defect represented 86/246
(35%) of the total study cohort.
The majority of our patients with PPS had uncompli-
cated PPS (30/39, 77%), meaning that they did not require
hospital readmission or invasive therapy to evacuate peri-
cardial or pleural effusions. Only a minority of the patients
in the total study cohort—9/246 patients (4%) and 9/39
patients (23%) in the PPS cohort—were diagnosed with
complicated PPS. There was no statistical difference in the
overall incidence of PPS (complicated and noncomplicated)
between the treatment group (21/126 [17%]) and control
group (18/120 [15%]) (p 5 0.73).
Short-term immunosuppression and postpericardiotomy
syndrome. Our data demonstrate that transient immuno-
suppression when systemic heart antigen exposure is pre-
sumably at its greatest is ineffective in blocking the initiation
of the inflammatory response that leads to the development
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of PPS. These findings challenge the conventionally ac-
cepted antigen-antibody immune complex mechanism as an
etiology for PPS. In fact, our data suggest a negative effect
of transient immunosuppression on PPS outcome. Of the
nine patients diagnosed with complicated PPS in our study,
a greater proportion of treatment group (8/126) versus
control group (1/120) patients had complicated PPS (p 5
0.05).
This finding raises an intriguing question regarding the
effect of transient immune suppression on the inflammatory
response. Cardiopulmonary bypass initiates a complex and
elaborate inflammatory reaction whose final clinical mani-
festation is dependent upon a delicate balance between
proinflammatory mediators and anti-inflammatory media-
tors. Each of these mediators exerts its effect at differing
times and at differing intensities within the inflammatory
cascade.
Steroids, like glucocorticoids, exert their anti-
inflammatory effects by a mechanism of action that involves
binding to an intracellular receptor, which is then trans-
ported into the nucleus where it affects messenger ribonu-
cleic acid transcription and, consequently, protein transla-
tion. Because alterations in the translation of specific
proteins are required, it is unlikely that the maximum effect
of the administered steroid is realized immediately (23).
In the management of sepsis, duration, as well as total
dosage, of glucocorticosteroid can greatly affect patient
outcome (24). Prolonged treatment with glucocorticoste-
roids is necessary to achieve a sustained reduction in
inflammatory mediators (25,26). Indeed, the inflammatory
response may be enhanced by a short course of glucocorti-
costeroid through a rebound phenomenon (27). A previous
investigator has speculated that in order for glucocortico-
steroids to have a positive impact on the treatment of
inflammatory conditions such as sepsis and adult respiratory
distress syndrome, its duration of therapy needs to be
prolonged (28).
In the clinical setting, it seems logical to counter the
deleterious effects of an inflammatory condition like PPS
with therapeutic agents like steroids (23). Elucidating the
exact time in the inflammatory cascade when steroids have
a maximum effect on each mediator, both proinflammatory
and anti-inflammatory, and defining the extent and dura-
tion of this effect are paramount to our understanding and
most essential to our effectively treating PPS and other
inflammatory conditions.
Study limitations. We provided a set of criteria for the
diagnosis of PPS to minimize the subjectivity of the
diagnosis and, for purposes of analysis, included only those
patients who achieved these criteria. However, PPS repre-
sents a clinical spectrum, and some centers may use more or
less stringent criteria for the diagnosis. Distinction between
noncomplicated and complicated PPS was more subjective
and may have influenced our results. Although we use
practice guidelines in the perioperative management of our
patients, we did not attempt to control individual caregivers
in the management of these patients nor did we interfere
with decisions related to hospitalization or invasive treat-
ment of these patients. Finally, we did not use an objective
means by which to measure the effectiveness of immune
suppression. We did not measure inflammatory mediators
such as tumor necrosis factor and interleukins 6 and 8. Our
principle objective was primary outcome based upon clini-
cally accepted immune suppression dosing.
Conclusions. We conclude that the prophylactic adminis-
tration of methylprednisolone at a standard anti-
inflammatory dose administered immediately before cardiac
surgery and in the early postoperative period neither pre-
vents nor attenuates PPS in children. The short-term
glucocorticosteroid treatment in the postcardiotomy patient
may, in fact, complicate PPS.
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